Built on the federal brief and all 51 jurisdiction briefs. It reads the federal landscape against the states, lever by lever, through the enclosure lens. Planning analysis, not legal advice.
In 2026 the same procedure runs from two directions at once. From the top, the federal government is medicalizing and standardizing drug policy in ways that reward the largest, best-capitalized players. From the bottom, the states are fencing their own markets through taxes, caps, and consolidation. The two fronts do not cancel; they compound. Federal action routes demand and advantage toward the incumbents, and state action builds the toll gates that collect it.
The federal stance in 2026 is best summarized as medicalize and control, not decriminalize. The April 2026 DOJ and DEA order moved only two narrow categories, FDA-approved cannabis drugs and state-licensed medical cannabis, to Schedule III, leaving recreational cannabis in Schedule I, with a broader rescheduling hearing that opened June 29, 2026 and may not resolve until 2027. Congress narrowed the federal definition of hemp to a total-THC standard, recriminalizing most intoxicating hemp products on November 12, 2026. Banking reform stalled. Psychedelics remain Schedule I while the FDA fast-tracks a pharmaceutical pathway. Harm-reduction funding was cut. Fentanyl analogues were permanently placed in Schedule I. Every one of these choices privileges the regulated, capitalized, compliance-heavy actor over the small, the informal, and the local. The federal enclosure read is 4 out of 5.
The federal move was deliberately narrow. Schedule III ended the punishing 280E tax only for state-licensed medical cannabis, eased research, and did nothing else: no federal legalization, no interstate commerce, and no cover for state recreational businesses, which remain federally illegal and still pay 280E.
Mapped onto the states, this splits the country in a revealing way. Medical-only states like Arkansas, Florida, Georgia, Mississippi, Utah, and West Virginia see their capped, often MSO-dominated medical operators get a real tax cut, which strengthens exactly the incumbents who already hold the licenses. The big adult-use markets that carry most of the nation's legal cannabis, California, Michigan, Washington, Illinois, Massachusetts, New Jersey, and others, get little or nothing from the order, because their volume is recreational and stays in Schedule I. The result is perverse from a commons standpoint: the federal tax break flows to the most enclosed, capped medical markets, not to the more open ones. And because a Schedule III drug normally requires FDA approval and a prescription, the order quietly points toward a future where the lawful path runs through pharma and FDA, not through a dispensary a small operator can open.
This is the single most important point of contact between federal and state policy in 2026, because it is the rare federal action that lands on every jurisdiction on the same day. The states were already sorted into three postures, and the federal ban resolves all three in the direction of enclosure.
States that had already banned intoxicating hemp are simply reinforced: Arkansas, Georgia, Idaho, South Dakota, Tennessee, Wyoming, Mississippi, and others were ahead of the federal curve, and November 12 hardens what they already did. States that chose to route intoxicating hemp into their licensed cannabis systems find the federal standard aligning with and accelerating that channeling: California through AB 8, plus Connecticut, Delaware, New Jersey, Nevada, Minnesota, and Washington. In both buckets the effect is the same, a sprawling, decentralized, often rural and small-business hemp economy is closed, and the demand is pushed toward the capped, taxed, frequently MSO-controlled cannabis channel. The most exposed states are the ones that still run an open intoxicating-hemp market, Wisconsin, North Carolina, Texas, and others, where the federal ban threatens to erase thousands of shops and jobs at a stroke. This is the enclosure algorithm performed nationally: abstract the plant into a federal total-THC unit, retitle what is lawful, and turn yesterday's legal product into tomorrow's contraband.
The SAFER Banking Act stalled, and momentum fell further once the Schedule III order arrived. The absence of a banking safe harbor is a flat, nationwide condition, but its weight is not flat. Large multistate operators can absorb the cost and friction of operating without normal banking; small and single-state operators cannot. So a federal non-action functions as an enclosure subsidy, quietly favoring scale in every state at once. The states that tried to keep markets open and local, through residency rules like Alaska's that keep the giants out, or small-grower tiers like Vermont's, are precisely the ones whose protected small operators are most squeezed by the federal banking gap.
Psychedelics in 2026 sit where cannabis sat fifteen years ago, and the federal-state interaction is the early warning. Federally, psilocybin, MDMA, and ibogaine remain Schedule I, while an April 2026 executive order and FDA priority vouchers fast-track a pharmaceutical approval pathway, with a Compass Pathways psilocybin application expected late in the year. Several states have moved ahead of Washington: Oregon and Colorado run live psilocybin service programs, New Mexico became the third state to authorize therapeutic psilocybin, and Utah runs pilots. This creates direct state-federal tension, most sharply in Colorado and Oregon, where a functioning state access model coexists with federal Schedule I status.
The decisive question is what an FDA approval would do. On current terms it would trigger a conditional federal rescheduling that privileges the approved pharmaceutical product, which is the enclosure move applied to a medicine before its commons is even fully open. The states show the alternative shape, supervised non-pharmaceutical access, which a pharma-gated federal pathway could marginalize. This is the precise dynamic Del Potter's Open Formulation is built to get ahead of, and the state map shows why the timing is now.
Here federal and state policy point in opposite directions, and the gap is a map of who is allowed to stay alive. The April 2026 SAMHSA guidance barred federal funds for fentanyl test strips, clean syringes, and sterile water, even as the administration's own National Drug Control Strategy endorsed test strips, a contradiction worth naming. The states diverge sharply. The Northeast and West run syringe services, broad naloxone access, legal test strips, and in Rhode Island, New York, and Vermont, sanctioned overdose prevention centers. Much of the South and Plains still treats test strips as paraphernalia, Texas and Indiana among them, and lacks authorized syringe services. The federal funding cut lands hardest on the states that built the most, pulling support out from under the strongest programs, while doing little in the states that never allowed them. The most basic commons, survival, is being fenced by a combination of federal defunding and state prohibition.
The HALT Fentanyl Act permanently placed fentanyl-related substances in Schedule I, a uniform federal hardening that sits atop widely varying state sentencing and expungement regimes. Where states have built automatic cannabis expungement, Minnesota, New York, Maryland, and others, record relief is real; where relief is petition-based or absent, it is largely theoretical. Federal cannabis expungement, carried only in stalled bills like the MORE Act, has not arrived. The pattern is consistent: punishment is nationalized and made permanent, while relief is left to the states and unevenly delivered.
Put the levers together and a single design appears, even though no one coordinated it. Federal reform is shaped to reward the actors who can navigate FDA approval, state licensing, and compliance at scale: large multistate operators, pharmaceutical companies, and banks. The hemp ban routes a decentralized small-business market into the licensed cannabis channel those same actors dominate. Schedule III hands a tax cut to capitalized medical incumbents. The banking gap favors whoever can operate without normal banking, which means the big. The psychedelics pathway points control toward approved pharmaceutical products. And the states, through caps, taxes, and consolidation, build the retail toll gates where the advantage is collected. The federal front abstracts and retitles; the state front tolls. That is the enclosure algorithm with its labor divided across two levels of government.
The clearest single proof is Ohio, where a voter-passed adult-use statute was rewritten by the legislature to cap licenses, kill the small-cultivator tier, and end the equity program. It shows the same move the federal hemp ban makes, performed at the state level against the people's own vote: a commons opened, then fenced.
On current terms, federal and state action align to advantage the same set: large multistate cannabis operators, pharmaceutical companies positioned for FDA-approved cannabinoid and psychedelic medicines, and the banks that will eventually serve them. Fenced out, again on both fronts, are small and craft cultivators, legacy operators who carried these plants through prohibition, the hemp sector's tens of thousands of small businesses, patients in restrictive medical states, people who rely on harm-reduction services now defunded, and the informal market that never had a path to the licensed channel in the first place. Social-equity programs, meant to seat the dispossessed, have been repeatedly captured by capital, in Arizona, Illinois, New York, and elsewhere, which is enclosure wearing the language of repair.
The map is not only a record of fences. It also shows where openings survive, and those are the leverage points. Home grow rights persist in most adult-use states and are the simplest decentralizing protection. Residency rules in Alaska and small-grower tiers in Vermont and Maine keep markets local and prove an open market is durable. The citizen-initiative process, where it exists, remains the route by which the public has repeatedly opened what legislatures would not, which is exactly why Idaho is trying to abolish it for drugs. Automatic expungement, sanctioned harm-reduction sites, and public-interest design are all counter-moves on the record. And against the specific federal threat of medicalized capture, the strongest move is to title the standard to the commons on purpose before it is privately owned, which is what a public-domain whole-plant formulation does. The states that scored most open, Alaska and Vermont, are living evidence that the choice was never only between corporate capture and prohibition.
Federal: November 12, 2026, the hemp cliff effective date, unless a delay measure is enacted first; the DEA broader-rescheduling hearing that opened June 29, 2026 and its scope and litigation; a possible first FDA psychedelic approval and the conditional rescheduling it would trigger; FY2027 appropriations riders on hemp, banking, and harm reduction; and the November 2026 midterms, which could reshape committee control over all of it.
State: which exposed hemp states (Wisconsin, North Carolina, Texas) move to ban or to channel before November 12; whether more legislatures follow Ohio in rewriting voter-passed laws; the next psychedelic-access states; and whether residency rules and small-grower tiers survive legal and commercial pressure.
Read together, the federal government and the fifty states are running the same enclosure procedure at two altitudes, and the work of the commons is to defend the openings that remain, home grow, local ownership, the ballot, harm reduction, and public-domain standards, before the two fronts close on each other.
Methodology: this synthesis draws on the 2026 federal brief and the 51 jurisdiction briefs in the Drug Policy Watch set, each independently researched and sourced, with sponsors marked unconfirmed where not verifiable. Enclosure scores are an editorial read defined in the spreadsheet legend. A planning analysis, not legal advice; confirm any single detail against the underlying brief and its cited sources before acting on it.
This work is free and reader-funded. No paywalls, no ads. This brief is independent and fully sourced, and reader contributions are what keep the 50-state coverage current and answerable to readers, not advertisers or owners.
If it helped you, please chip in $5 to keep it going. Recurring support helps most; about $25 funds a full refresh of a state brief like this one.
A planning snapshot for 2026, not legal advice. Policy moves quickly; confirm any single detail against the cited sources before acting on it. Sponsor names are given where confirmable and marked unconfirmed otherwise.